化合物 T24524
化合物 T24524 性质
| 沸点 | 723.1±62.0 °C(Predicted) |
|---|---|
| 密度 | 1.23±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：100mM；乙醇：100 mM |
| 形态 | 固体 |
| 酸度系数(pKa) | 6.69±0.50(Predicted) |
| 颜色 | 白色至黄色 |
化合物 T24524 用途与合成方法
IC50: 11.6 nM (human C5aR)
NDT 9513727 inhibits C5a-stimulated responses, including guanosine 5'-3-O-(thio)triphosphate binding, Ca
2+
mobilization, oxidative burst, degranulation, cell surface CD11b expression and chemotaxis in various cell types with IC
50
s from 1.1 to 9.2 nM, respectively.
NDT 9513727 (3-30 mg/kg; p.o.) exhibits a dose-dependent inhibition of hC5a-induced neutropenia.
NDT 9513727 exhibits moderate oral bioavailability (rat 73%, monkey 26%) and C
max
(rat 5.98 μM, monkey 830 nM) following oral administration (rat 50, monkey 25.2 mg/kg).
NDT 9513727 exhibits moderate plasma elimination half-lives (rat 4.8, monkey 7.9 h) due to low plasma clearance (1.4 L/h/kg and 3.8 l/h/kg respectively) following oral administration (rat 50, monkey 25.2 mg/kg).
| Animal Model: | Six-week-old Mongolian gerbils |
| Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg |
| Administration: | Oral administration |
| Result: | Significantly inhibited hC5a-induced neutropenia at 3 mg/kg, 10 mg/kg, 30 mg/kg. |
| Animal Model: | Rat |
| Dosage: | 50 mg/kg |
| Administration: | Oral administration |
| Result: | Oral bioavailability (73%), C max (5.98 μM), T 1/2 (4.8 h). |
| Animal Model: | Monkey |
| Dosage: | 25.2 mg/kg |
| Administration: | Oral administration |
| Result: | Oral bioavailability (26%), C max (830 nM), T 1/2 (7.9 h). |
化合物 T24524 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-02-08 | HY-110060 | 化合物 T24524 | 439571-48-9 | 5 mg | 800 |
| 2025-02-08 | HY-110060 | 化合物 T24524 | 439571-48-9 | 10 mM * 1 mLin DMSO | 1010 |
